Cited by 130Pancreatic and Hepatic Oncology ResearchTGF-β signaling in diseasesCancer, Lipids, and Metabolism

Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion

Open access
Jiang, Hong, Liu, Xiuting, Knolhoff, Brett L, Hegde, Samarth, Lee, Kyung Bae, Jiang, Hongmei, Fields, Ryan C, Pachter, Jonathan A +2 more·2020·Gut

Abstract

Objective: We investigated how pancreatic cancer developed resistance to focal adhesion kinase (FAK) inhibition over time. Design: Pancreatic ductal adenocarcinoma (PDAC) tumours from KPC mice (p48-CRE; LSL-KRas G12D/wt ; p53 flox/wt ) treated with FAK inhibitor were analysed for the activation of a compensatory survival pathway in resistant tumours. We identified pathways involved in the regulation of signal transducer and activator of transcription 3 (STAT3) signalling on FAK inhibition by gene set enrichment analysis and verified these outcomes by RNA interference studies. We also tested combinatorial approaches targeting FAK and STAT3 in syngeneic transplantable mouse models of PDAC and KPC mice. Results: In KPC mice, the expression levels of phosphorylated STAT3 (pSTAT3) were increased in PDAC cells as they progressed on FAK inhibitor therapy. This progression corresponded to decreased collagen density, lowered numbers of SMA + fibroblasts and downregulation of the transforming growth factor beta (TGF-β)/SMAD signalling pathway in FAK inhibitor-treated PDAC tumours. Furthermore, TGF-β production by fibroblasts in vitro drives repression of STAT3 signalling and enhanced responsiveness to FAK inhibitor therapy. Knockdown of SMAD3 in pancreatic cancer cells abolished the inhibitory effects of TGF-β on pSTAT3. We further found that tumour-intrinsic STAT3 regulates the durability of the antiproliferative activity of FAK inhibitor, and combinatorial targeting of FAK and Janus kinase/STAT3 act synergistically to suppress pancreatic cancer progression in mouse models. Conclusion: Stromal depletion by FAK inhibitor therapy leads to eventual treatment resistance through the activation of STAT3 signalling. These data suggest that, similar to tumour-targeted therapies, resistance mechanisms to therapies targeting stromal desmoplasia may be critical to treatment durability.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2018-317424

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jiang, H., Liu, X., Knolhoff, B. L., Hegde, S., Lee, K. B., Jiang, H., Fields, R. C., Pachter, J. A., Lim, K.-H., & DeNardo, D. G.
Affiliations
  • Washington University in St. Louis (US)
  • Verastem (United States) (US)
Corresponding author
DeNardo, David G
Venue
Gut
Publisher
BMJ
Published
2019-05-10
Volume
69
Issue
1
Pages
122-132
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2944210961
Cited by
130
References
6
Citations by year
2026: 10 · 2025: 8 · 2024: 22 · 2023: 20 · 2022: 22 · 2021: 28 · 2020: 17 · 2019: 3
FWCI
7.31
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
David G. DeNardo
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
pancreatic ductal adenocarcinoma, focal adhesion kinase inhibition, drug resistance, STAT3 signaling, tumor stroma, desmoplasia, cancer-associated fibroblasts, KPC mice, Janus kinase inhibition, combination therapy, collagen density
MeSH terms
Aminopyridines, Animals, Antineoplastic Agents, Collagen, Female, Fibroblasts, Humans, Mice, Inbred Strains, Pancreatic Neoplasms, Signal Transduction, Down-Regulation, Transforming Growth Factor beta, Stromal Cells, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, Xenograft Model Antitumor Assays, STAT3 Transcription Factor, Focal Adhesion Protein-Tyrosine Kinases, Smad3 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review